Cargando…
Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
Sarcomas are rare and heterogeneous mesenchymal tumors affecting both pediatric and adult populations with more than 70 recognized histologies. Doxorubicin and ifosfamide have been the main course of therapy for treatment of sarcomas; however, the response rate to these therapies is about 10–20% in...
Autores principales: | Kreahling, Jenny M., Foroutan, Parastou, Reed, Damon, Martinez, Gary, Razabdouski, Tiffany, Bui, Marilyn M., Raghavan, Meera, Letson, Douglas, Gillies, Robert J., Altiok, Soner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592874/ https://www.ncbi.nlm.nih.gov/pubmed/23520471 http://dx.doi.org/10.1371/journal.pone.0057523 |
Ejemplares similares
-
Diffusion MRI and Novel Texture Analysis in Osteosarcoma Xenotransplants Predicts Response to Anti-Checkpoint Therapy
por: Foroutan, Parastou, et al.
Publicado: (2013) -
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018) -
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2017) -
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018) -
p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
por: Hauge, Sissel, et al.
Publicado: (2019)